Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $9.29M |
| Net Income (Most Recent Fiscal Year) | $-40.67M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -507.87% |
| Net Margin (Trailing 12 Months) | -507.87% |
| Return on Equity (Trailing 12 Months) | -228.43% |
| Return on Assets (Trailing 12 Months) | -114.66% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.67 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 75.35M |
| Free Float | 66.11M |
| Market Capitalization | $45.36M |
| Average Volume (Last 20 Days) | 0.16M |
| Beta (Past 60 Months) | 1.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.26% |
| Percentage Held By Institutions (Latest 13F Reports) | 35.04% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |